HomeClinics HomeAbout ClinicsAll ClinicsHot TopicsAdvancesSpecial OffersCME
Logo
Search for

Volume 55, Issue 1, Pages 1-20 (February 2008)


View previous. 5 of 17 View next.

Biology and Treatment of Acute Lymphoblastic Leukemia

Rob Pieters, MD, MSc, PhDaCorresponding Author Informationemail address, William L. Carroll, MDb

Acute lymphoblastic leukemia (ALL), the most common type of cancer in children, is a heterogeneous disease in which many genetic lesions result in the development of multiple biologic subtypes. Today, with intensive multiagent chemotherapy, most children who have ALL are cured. The many national or institutional ALL therapy protocols in use tend to stratify patients in a multitude of different ways to tailor treatment to the rate of relapse. This article discusses the factors used in risk stratification and the treatment of pediatric ALL.

a Department of Pediatric Oncology and Hematology, Erasmus MC-Sophia Children's Hospital, Dr Molewaterplein 60, 3015GJ Rotterdam, The Netherlands

b Division of Pediatric Hematology/Oncology, New York University Medical Center, 160 East 32nd Street, 2nd Floor, New York, NY 10016, USA

Corresponding Author InformationCorresponding author.

PII: S0031-3955(07)00174-5

doi:10.1016/j.pcl.2007.11.002


View previous. 5 of 17 View next.